Burning Rock Biotech Limited (BNR)
BNR Stock Price Chart
Explore Burning Rock Biotech Limited interactive price chart. Choose custom timeframes to analyze BNR price movements and trends.
BNR Company Profile
Discover essential business fundamentals and corporate details for Burning Rock Biotech Limited (BNR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
12 Jun 2020
Employees
674.00
Website
https://www.brbiotech.comCEO
Yusheng Han
Description
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
BNR Financial Timeline
Browse a chronological timeline of Burning Rock Biotech Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 8 Sept 2025
EPS came in at -$0.15 .
Earnings released on 28 Aug 2025
EPS came in at -$0.14 .
Earnings released on 6 Jun 2025
EPS came in at -$0.17 , while revenue for the quarter reached $18.28M .
Earnings released on 25 Mar 2025
EPS came in at -$1.08 surpassing the estimated -$1.40 by +22.69%, while revenue for the quarter reached $17.26M .
Earnings released on 3 Dec 2024
EPS came in at -$0.50 surpassing the estimated -$1.41 by +64.55%, while revenue for the quarter reached $18.33M .
Earnings released on 22 Aug 2024
EPS came in at -$0.14 surpassing the estimated -$1.49 by +90.58%, while revenue for the quarter reached $18.65M .
Earnings released on 29 May 2024
EPS came in at -$0.16 surpassing the estimated -$1.52 by +89.49%, while revenue for the quarter reached $17.37M .
Stock split effective on 15 May 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Mar 2024
EPS came in at -$2.20 , while revenue for the quarter reached $17.10M , beating expectations by +11.73%.
Earnings released on 30 Nov 2023
EPS came in at -$2.30 falling short of the estimated -$1.81 by -27.25%, while revenue for the quarter reached $17.46M , missing expectations by -13.26%.
Earnings released on 31 Aug 2023
EPS came in at -$1.80 surpassing the estimated -$1.89 by +4.70%, while revenue for the quarter reached $20.19M , beating expectations by +0.29%.
Earnings released on 30 May 2023
EPS came in at -$2.60 falling short of the estimated -$2.00 by -30.00%, while revenue for the quarter reached $20.73M , beating expectations by +2.96%.
Earnings released on 28 Mar 2023
EPS came in at -$3.10 falling short of the estimated -$0.38 by -715.79%, while revenue for the quarter reached $20.77M , beating expectations by +27.45%.
Earnings released on 15 Nov 2022
EPS came in at -$3.10 falling short of the estimated -$2.80 by -10.71%, while revenue for the quarter reached $21.64M , beating expectations by +0.34%.
Earnings released on 31 Aug 2022
EPS came in at -$3.70 falling short of the estimated -$3.60 by -2.78%, while revenue for the quarter reached $19.52M , missing expectations by -13.93%.
Earnings released on 31 May 2022
EPS came in at -$3.90 falling short of the estimated -$2.30 by -69.57%, while revenue for the quarter reached $21.33M , missing expectations by -2.24%.
Earnings released on 21 Mar 2022
EPS came in at -$3.80 falling short of the estimated -$0.24 by -1.51K%, while revenue for the quarter reached $23.14M , beating expectations by +7.70%.
Earnings released on 15 Nov 2021
EPS came in at -$2.50 falling short of the estimated -$1.90 by -31.58%, while revenue for the quarter reached $19.62M , missing expectations by -6.00%.
Earnings released on 31 Aug 2021
EPS came in at -$3.00 falling short of the estimated -$1.50 by -100.00%, while revenue for the quarter reached $19.68M .
Earnings released on 25 May 2021
EPS came in at -$2.50 falling short of the estimated -$1.40 by -78.57%, while revenue for the quarter reached $16.24M .
Earnings released on 10 Mar 2021
EPS came in at -$2.30 falling short of the estimated -$1.60 by -43.75%, while revenue for the quarter reached $20.18M .
Earnings released on 20 Nov 2020
EPS came in at -$1.80 falling short of the estimated -$1.10 by -63.64%, while revenue for the quarter reached $18.23M .
BNR Stock Performance
Access detailed BNR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.